肝性脑病中医/壮医“浊毒致病”理论及防治策略的构建与实践
DOI: 10.12449/JCH250226
Construction and practice of the theory of “turbid toxin pathogenesis” and related prevention and treatment strategies for hepatic encephalopathy in traditional Chinese medicine/Zhuang medicine
-
摘要: 肝性脑病为肝病领域的疑难危重疾病,进展迅速、治疗手段有限、发病机制亟待突破。选择合适的防治策略,对于延缓疾病进展、降低发病率和病死率起到重要作用。本文就中医/壮医肝性脑病“浊毒致病”理论及防治策略进行述评,提出肝性脑病中医/壮医“浊毒致病”新学说,解析“浊”“毒”及“浊毒致病”理论的科学内涵,构建肝性脑病“四步曲”防治策略,并以此为基础延伸出以“四方两技法”为代表的肝性脑病临床防治新方案,继而阐明核心方药与技法防治肝性脑病的效应机制与生物学基础,以期为肝性脑病的防治提供参考。Abstract: Hepatic encephalopathy is a difficult and critical disease with rapid progression and limited treatment methods in the field of liver disease, and it is urgently needed to make breakthroughs in its pathogenesis. Selection of appropriate prevention and treatment strategies is of great importance in delaying disease progression and reducing the incidence and mortality rates. This article reviews the theory of “turbid toxin pathogenesis” and related prevention and treatment strategies for hepatic encephalopathy in traditional Chinese medicine/Zhuang medicine, proposes a new theory of “turbid toxin pathogenesis”, analyzes the scientific connotations of “turbid”, “toxin”, and the theory of “turbid toxin pathogenesis”, and constructs the “four-step” prevention and treatment strategies for hepatic encephalopathy, thereby establishing the new clinical prevention and treatment regimen for hepatic encephalopathy represented by “four prescriptions and two techniques” and clarifying the effect mechanism and biological basis of core prescriptions and techniques in the prevention and treatment of hepatic encephalopathy, in order to provide a reference for the prevention and treatment of hepatic encephalopathy.
-
Key words:
- Hepatic Encephalopathy /
- Turbid Toxin Pathogenic /
- Therapeutics
-
肝性脑病是严重肝病引起的,以代谢紊乱为基础、中枢神经系统功能失调为主的临床综合征,是重症肝病常见致死性并发症[1]。在我国,肝衰竭并发肝性脑病的临床救治最为棘手,有研究显示肝性脑病发病3年后存活率仅为23%,降氨、抗炎、醒脑等综合治疗手段尚未能将肝衰竭并发肝性脑病治疗有效率提升至50%以上[2]。近年来,肝性脑病综合治疗手段得到了长足的发展,但现代医学治疗肝性脑病的方法尚存在作用范围有限、不良反应较多、经济负担偏重等不足[3]。传统中医/壮医具有一定的疗效与经济优势,但也存在着对病因病机及病位的认识尚未清晰、理论创新不足、操作流程欠规范、疗效机制待明确等问题,以致成为阻碍中医/壮医在肝性脑病防治方面发挥优势的关键技术闩锁。有鉴于此,本课题组历时近20年潜心攻关,在以中医药为主线的基础上充分融合广西壮医药特色优势,形成了肝性脑病的中医/壮医防治策略。
1. 肝性脑病中医/壮医“浊毒致病”新学说
肝性脑病归属于中医学“黄疸”“肝厥”等范畴。从古至今,诸多医家对肝性脑病中医病因病机的认识多受限于“痰蒙神窍”的传统思维之中[4-5]。壮医学则提出肝性脑病核心致病机制为“毒”邪盘踞,阻滞“三道两路”致使浊毒侵袭“巧坞”(脑),发为本病[6]。课题组经过长期临床实践与大量前期研究,并结合广西地域壮医药优势,突破“痰蒙神窍”“毒邪致病”的桎梏,创新性提出完整的肝性脑病“浊毒致病”新学说,初步厘清“浊”“毒”既是肝性脑病致病之因,又是病理产物,“浊”→“毒”→“浊毒”,由微至极,共同介导了肝性脑病的发生及发展[7]。具体来说,肝性脑病基础疾病在疾病进程中可产生“湿”“热”“痰”“瘀”等病邪,“浊”是在“湿”“热”“痰”“瘀”等病邪的基础上兼夹伴生的病理产物,这些病理产物在体内形成后若化解不及时,则可进一步积聚成浊,成浊后进一步阻碍气机、阻滞血脉及蒙蔽神窍,浊盛而成“毒”,“浊毒”致使肝性脑病典型发作[5, 7]。
2. 肝性脑病“浊”“毒”及“浊毒致病”理论的科学内涵
肝性脑病的发病机制有待完善,氨中毒学说、肠道菌群失调是当前现代医学主流的发病机制假说[8]。本课题组前期研究即发现肝性脑病患者氨代谢异常,肠道菌群紊乱及肠道微环境改变与肝性脑病的发生密切相关[9-10]。现代医学中血氨、肠道菌群与中医“浊”的概念不谋而合,内毒素与中医“毒”的概念异曲同工[11]。目前认为,肝性脑病主要源于紊乱肠道菌群和持续受损的肠道功能障碍,导致血氨、内毒素等产生、吸收增多,加之肝功能衰竭,其解毒能力下降,毒素在体内高度富集,损害脑神经系统而发病[8]。同时,内毒素又可通过刺激单核巨噬细胞产生IL-18、IL-6等细胞炎症因子,间接引发炎症“二次打击”效应,导致病情进一步恶化,内毒素血症发展为炎症“二次打击”效应介导了肝性脑病的发病或者病情加重的过程,可视为由“浊”→“毒”→“浊毒”嬗变的过程[11]。从免疫应激损伤、血氨累积、肠道菌群紊乱等层面阐明肝性脑病“浊”“毒”及“浊毒致病”理论的科学内涵,为肝性脑病临床治疗提供了新思路。
3. 肝性脑病“四步曲”防治策略(图1)
3.1 第一步曲:“浊邪”未成,使邪有出路,防诸邪日久生浊(潜伏期)
该阶段“浊邪”未成,尚未见“浊邪”上扰神明、蒙蔽清窍之症,以处理肝脏基础疾病(肝硬化、肝癌、肝衰竭)所生“湿”“痰”“瘀”诸邪为主,兼顾患者久病体虚为辅。运用“祛湿”“化痰”“化瘀”“补虚”等法从源头上干预,既有迎头抗邪之功,又有防芽遏萌之妙。方选三仁分消饮,方中酌用杏仁、白蔻仁、陈皮、石菖蒲、薏苡仁祛湿化痰,郁金、赤芍、丹参活血化瘀,红景天、白术、茯神兼能补虚,根据诸邪侧重,辨证施药,祛原发疾病之邪,避免日久产生浊邪[12]。
3.2 第二步曲:“浊邪”初成,宣畅三焦、降气化浊,遏邪于萌芽(前驱期)
该阶段诸邪日久初生“浊邪”,易扰心神、蒙蔽脑窍,临床症见夜寐不安,欣快激动或淡漠少言。此时“浊邪”尚轻,尚易化解,但有邪势渐升之虞,故治当宣畅三焦,降气化浊,可予六味醒神颗粒治之。方中胆南星、石菖蒲豁痰开窍,清三焦流窜浊邪;法半夏、枇杷叶燥湿化痰,清上焦肺气以降浊邪;白术、茯神健脾化湿化中焦浊邪[13]。
3.3 第三步曲:“浊毒”俱蕃,清热解毒、化浊开窍,驱浊毒之邪尽出(发作期)
该阶段“浊毒”俱蕃,流窜心脑,狂、躁、昏俱备。患者出现神志改变拒绝服药,首当解毒化浊、通腑开窍,驱浊毒之邪尽出,运用大黄煎剂保留灌肠,使浊毒之邪从下而出,并联合运用壮医针刺疗法针刺双侧猫爪尖穴(十指指尖)解毒化浊、开窍醒神,先解“拒药”之虑。内服方药可予解毒化瘀方,方中大黄、茵陈、白花蛇舌草、赤芍清热解毒化浊,郁金、石菖蒲解毒化浊开窍[14]。该阶段内服与外治联合多管齐下疗效倍加。
3.4 第四步曲:“浊毒”已散,扶正兼顾祛邪,防邪留恋(恢复期)
该阶段“浊毒”已散,但邪散正虚,正虚之时,“浊毒”仍可再聚为患。治以扶正补虚、调节阴阳为主,兼顾解毒化浊,以防“浊毒”复聚,可予温阳化瘀退黄方,方中附片、白术、薏苡仁补火助阳健脾祛湿以化浊,茵陈、虎杖、赤芍、丹参、郁金清热凉血活血化瘀以解毒[15]。同时,合用六味醒神颗粒,诸药共会“扶正兼顾祛邪,防邪留恋”之意。
4. 以“四方两技法”为代表的肝性脑病临床防治新方案
肝性脑病临床症状极其复杂、变化迅速,尤其晚期患者更是诸脏俱损,诸症并存,虚实夹杂,寒热错杂,导致临床中医师难以进行准确的辨证论治,往往是药到证已改,严重影响治疗效果稳定性。有鉴于此,课题组根据肝性脑病中医/壮医病机理论新认识及“四步曲”防治策略,经过反复临床实践与优化,形成了针对肝性脑病4期病症辨病论治的系列方药及治法,具体方药如下:(1)潜伏期(“浊邪”未成):基本病机为久病体虚,痰、湿、瘀三气胶结,治疗原则为祛痰化湿、扶正化瘀,核心方药为三仁分消饮;(2)前驱期(“浊邪”初成):基本病机为浊邪上逆,流窜三焦,治疗原则为宣畅三焦、降气化浊,核心方药为六味醒神颗粒;(3)发作期(“浊毒”俱蕃):基本病机为热毒炽盛、浊邪闭阻清窍,治疗原则为清热解毒,化浊开窍,核心方药为解毒化瘀方,核心技法为大黄煎剂保留灌肠、壮医针刺疗法;(4)恢复期(“浊毒”已散):基本病机为正气亏虚、恢复阴阳平衡,治疗原则为扶正补虚、调节阴阳为主,兼顾解毒化浊,核心方药为温阳化瘀退黄方合用六味醒神颗粒。
5. 核心方药及技法防治肝性脑病的效应机制与生物学基础
5.1 六味醒神颗粒
六味醒神颗粒治疗肝性脑病可见总有效率从76.0%提高至92.3%,其机制在于降低肝性脑病患者血氨、内毒素、细胞炎症因子水平,通过降低血脑屏障通透性、调节肠道菌群代谢,减少内毒素血症的发生,进而改善患者神经生理功能[16]。此外,六味醒神颗粒可有效改善肝性脑病患者中医证候积分、数字连接试验-A分值和数码符号试验分值(P<0.05),短期疗效与乳果糖基本相当[17]。实验研究与网络药理学分子对接研究亦发现六味醒神颗粒能调控血脑屏障通透性、影响肠道菌群结构及功能代谢,改善肝性脑病患者认知功能障碍[18-19]。
5.2 大黄煎剂保留灌肠
多中心、随机、平行对照临床研究发现大黄煎剂保留灌肠治疗肝性脑病患者的总有效率由60.83%提高到86.00%,并将患者的苏醒时间缩短至(7.4±1.5)h以内,同时降低人均住院费用,整体临床疗效优于西药和传统中医治疗方法[20-21]。有研究通过正交实验方法,对该技术中的药液温度、插管深度、保留时间、灌肠后体位等影响疗效的关键性因素的具体参数进行优化研究,形成规范的临床操作和护理规程,可提升临床疗效[22-24]。实验研究揭示大黄煎剂保留灌肠拮抗肝性脑病的作用机制与调控PI3K/AKT/mTOR信号通路,改善轻微型肝性脑病大鼠认知功能及脑组织炎症损伤有关[25]。基于16S rDNA基因测序和胆汁酸代谢组学的研究显示大黄煎剂保留灌肠显著改善肝性脑病大鼠的肝功能,降低血氨水平,减轻脑水肿并恢复认知功能,还能逆转肠道菌群紊乱并调节胆汁酸代谢[26-27]。
5.3 解毒化瘀方
临床研究表明解毒化瘀方能改善肝性脑病患者智力水平和神经电生理学检查指标,进而提高患者认知功能与神经生理功能,临床疗效优于单用乳果糖[28-29]。实验研究表明解毒化瘀方通过降低血氨水平,促进血氨的代谢及通过保护脑线粒体的结构,恢复脑神经元功能以治疗肝性脑病[30]。同样,一项随机平行对照研究亦表明解毒化瘀方能改善肝性脑病大鼠血浆内毒素、血氨、肝脏病理等指标[14]。
6. 总结与展望
肝性脑病发病迅速、病情凶险、病死率高。由于肝性脑病的发病机制尚不完全明确,目前尚无特异性治疗方法,因而找到肝性脑病治疗的最佳途径是肝病学界科研攻关的热点与难题,同样也是需要重点关注和亟待解决的重大社会公共卫生问题。本课题组毛德文教授在前人认识基础上结合广西地域壮医药优势,提出了肝性脑病“浊毒致病”新学说。在该理论的指导下采用中医/壮医对肝性脑病进行按疾病分期、分阶段辨证次第治疗,有望成为肝性脑病防治的新策略。本文为课题组20年间的截断面研究成果总结,部分方药与技法的后续研究还在跟进,今后的研究将继续完善核心方药与技法防治肝性脑病的效应机制与生物学基础;同时,在现有应用基础上,加强核心方药的转化力度,打造新药产业化链条,助推疑难重症疾病中医药治疗的新发展。
-
[1] ROSE CF, AMODIO P, BAJAJ JS, et al. Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy[J]. J Hepatol, 2020, 73( 6): 1526- 1547. DOI: 10.1016/j.jhep.2020.07.013. [2] TAPPER EB, PARIKH ND. Diagnosis and management of cirrhosis and its complications: A review[J]. JAMA, 2023, 329( 18): 1589- 1602. DOI: 10.1001/jama.2023.5997. [3] WANG XB, SHI K. Integrated traditional Chinese and western medicine diagnosis and treatment of hepatic encephalopathy: Advances and perspectives[J]. J Clin Hepatol, 2022, 38( 9): 1969- 1973. DOI: 10.3969/j.issn.1001-5256.2022.09.004.王宪波, 时克. 肝性脑病的中西医结合诊疗进展与展望[J]. 临床肝胆病杂志, 2022, 38( 9): 1969- 1973. DOI: 10.3969/j.issn.1001-5256.2022.09.004. [4] WAN LF. Clinical experience of chief physician SHAO Ming treating hepatic encephalopathy[J]. J Chengdu Univ Tradit Chin Med, 2010, 33( 3): 38, 44. DOI: 10.13593/j.cnki.51-1501/r.2010.03.010.万凌峰. 邵铭主任医师辨证论治肝性脑病经验[J]. 成都中医药大学学报, 2010, 33( 3): 38, 44. DOI: 10.13593/j.cnki.51-1501/r.2010.03.010. [5] JIANG HN, MAO DW, YE QL, et al. Research progress on TCM syndrome differentiation and treatment of hepatic encephalopathy[J]. Shaanxi J Tradit Chin Med, 2020, 41( 11): 1678- 1680. DOI: 10.3969/j.issn.1000-7369.2020.11.042.蒋海南, 毛德文, 叶倩伶, 等. 中医辨证论治肝性脑病研究进展[J]. 陕西中医, 2020, 41( 11): 1678- 1680. DOI: 10.3969/j.issn.1000-7369.2020.11.042. [6] PANG YZ, LI WW. Zhuang Medicine internal pediatrics[M]. Beijing: China Press of Traditional Chinese Medicine, 2018.庞宇舟, 李伟伟. 壮医内儿科学[M]. 北京: 中国中医药出版社, 2018. [7] BAI WJ, PAN PP, SHI QL, et al. Discussion on the pathogenic theory of“turbidity-toxin” in hepatic encephalopathy[J]. J Basic Chin Med, 2023, 29( 5): 727- 730. DOI: 10.19945/j.cnki.issn.1006-3250.2023.05.005.柏文婕, 潘佩佩, 石清兰, 等. 基于“浊毒致病”学说探讨肝性脑病病因病机[J]. 中国中医基础医学杂志, 2023, 29( 5): 727- 730. DOI: 10.19945/j.cnki.issn.1006-3250.2023.05.005. [8] Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the management of hepatic encephalopathy in cirrhosis[J]. J Clin Hepatol, 2018, 34( 10): 2076- 2089. DOI: 10.3969/j.issn.1001-5256.2018.10.007.中华医学会肝病学分会. 肝硬化肝性脑病诊疗指南[J]. 临床肝胆病杂志, 2018, 34( 10): 2076- 2089. DOI: 10.3969/j.issn.1001-5256.2018.10.007. [9] LIN Y, YAN GJ, FENG F, et al. Characterization of intestinal microbiota and serum metabolites in patients with mild hepatic encephalopathy[J]. Open Life Sci, 2022, 17( 1): 139- 154. DOI: 10.1515/biol-2021-0140. [10] TANG YF, LIU XD, WANG WX, et al. Clinical characteristics and relatedinfluencing factors of minimalhepatic encephalopathy in patients with liver cirrhosis[J]. Infect Dis Inf, 2022, 35( 4): 316- 320. DOI: 10.3969/j.issn.1007-8134.2022.04.006.唐艳芳, 刘旭东, 王文鑫, 等. 肝硬化合并轻微型肝性脑病的临床特点以及相关影响因素分析[J]. 传染病信息, 2022, 35( 4): 316- 320. DOI: 10.3969/j.issn.1007-8134.2022.04.006. [11] WANG TS, ZHANG RZ, WANG MG, et al. Theoretical connotations of liver failure“toxic pathogen-toxic turbidity” theory from the angle of“gut-liver axis”[J]. West J Tradit Chin Med, 2022, 35( 6): 67- 70. DOI: 10.12174/j.issn.2096-9600.2022.06.18.王挺帅, 张荣臻, 王明刚, 等. 从“肠肝轴”角度诠释肝衰竭“毒邪-毒浊”学说的理论内涵[J]. 西部中医药, 2022, 35( 6): 67- 70. DOI: 10.12174/j.issn.2096-9600.2022.06.18. [12] SHI QL, HUANG ZH, BAI WJ, et al. Construction and practice of“four-step”prevention and treatment strategy for hepatic encephalopathy[J]. Chin J Integr Tradit West Med Liver Dis, 2023, 33( 2): 166- 168. DOI: 10.3969/j.issn.1005-0264.2023.002.019.石清兰, 黄祖鸿, 柏文婕, 等. 肝性脑病“四步曲”防治策略的构建与实践[J]. 中西医结合肝病杂志, 2023, 33( 2): 166- 168. DOI: 10.3969/j.issn.1005-0264.2023.002.019. [13] WANG S, WANG N, MAO DW, et al. Clinical observation on the effect of Liuwei xingshen granules combined with mirabilite retention Enema in the treatment of type C hepatic encephalopathy and the regulation of acid-base imbalance[J]. Tradit Chin Med J, 2023, 22( 11): 28- 31. DOI: 10.14046/j.cnki.zyytb2002.2023.11.015.王沙, 王娜, 毛德文, 等. 六味醒神颗粒加芒硝保留灌肠治疗C型肝性脑病及调节酸碱失衡作用的临床观察[J]. 中医药通报, 2023, 22( 11): 28- 31. DOI: 10.14046/j.cnki.zyytb2002.2023.11.015. [14] YAO C, XIE W, FU L. Jiedu Huayu Decoction science, learning and memory in the rats' behavior of the minor hepatic encephalopathy, toxins, ammonia, liver function and liver pathology affect plasma randomized controlled research[J]. J Pract Tradit Chin Intern Med, 2012, 26( 5): 7- 10. DOI: 10.3969/j.issn.1671-7813.2012.05.04.姚春, 谢武, 付蕾. 解毒化瘀方对轻微型肝性脑病大鼠行为学、学习记忆能力、血浆内毒素、血氨、肝功能及肝脏病理影响随机平行对照研究[J]. 实用中医内科杂志, 2012, 26( 5): 7- 10. DOI: 10.3969/j.issn.1671-7813.2012.05.04. [15] LYU C, MAO DW, QIN Q, et al. Effect of Wenyang Huayu Tuihuang Decoction in the treatment of hepatitis B-related chronic and acute liver failure[J]. China Med Herald, 2019, 16( 30): 142- 146.吕超, 毛德文, 覃倩, 等. 温阳化瘀退黄方治疗乙型肝炎相关慢加急性肝衰竭的效果[J]. 中国医药导报, 2019, 16( 30): 142- 146. [16] MA YZ, MAO DW, QIN YX, et al. Clinical effects of Liuwei xingshen granules in treating mild hepatic encephalopathy of liver cirrhosis and its influence on blood ammonia and endotoxin[J]. West J Tradit Chin Med, 2021, 34( 5): 7- 10. DOI: 10.12174/j.issn.2096-9600.2021.05.03.马玉珍, 毛德文, 覃艳新, 等. 六味醒神颗粒治疗肝硬化轻微型肝性脑病的临床疗效及其对血氨和内毒素的影响[J]. 西部中医药, 2021, 34( 5): 7- 10. DOI: 10.12174/j.issn.2096-9600.2021.05.03. [17] WANG MG, WANG N, MAO DW, et al. The clinical research into minimal hepatic encephalopathy treated with Liuwei xingshen granule[J]. Henan Tradit Chin Med, 2016, 36( 12): 2112- 2114. DOI: 10.16367/j.issn.1003-5028.2016.12.0843.王明刚, 王娜, 毛德文, 等. 六味醒神颗粒治疗轻微型肝性脑病临床研究[J]. 河南中医, 2016, 36( 12): 2112- 2114. DOI: 10.16367/j.issn.1003-5028.2016.12.0843. [18] WANG MG, MAO DW, WANG N, et al. Experimental study on regulating blood-brain barrier permeability of rats with mild hepatic encephalopathy by Liuwei Xingshen Granule[J]. Lishizhen Med Mater Med Res, 2016, 27( 7): 1619- 1621. DOI: 10.3969/j.issn.1008-0805.2016.07.027.王明刚, 毛德文, 王娜, 等. 六味醒神颗粒调控轻微型肝性脑病大鼠血脑屏障通透性的实验研究[J]. 时珍国医国药, 2016, 27( 7): 1619- 1621. DOI: 10.3969/j.issn.1008-0805.2016.07.027. [19] WU N, MAO XK, WANG MG. Molecular mechanism of Liuwei xingshen granule(六味醒神颗粒) against hepatic encephalopathy based on network pharmacology and molecular docking[J]. Guid J Tradit Chin Med Pharm, 2020, 26( 5): 88- 92. DOI: 10.13862/j.cnki.cn43-1446/r.2020.05.023.吴娜, 毛祥坤, 王明刚. 基于网络药理学及分子对接研究六味醒神颗粒治疗肝性脑病的分子作用机制[J]. 中医药导报, 2020, 26( 5): 88- 92. DOI: 10.13862/j.cnki.cn43-1446/r.2020.05.023. [20] HUANG GY, MAO DW, LONG FL, et al. Retention Enema with rhubarb decoction in treating hepatic encephalopathy: Results from a multi-center clinical trial[J]. Liaoning J Tradit Chin Med, 2011, 38( 7): 1364- 1366. DOI: 10.13192/j.ljtcm.2011.07.118.huanggy.032.黄古叶, 毛德文, 龙富立, 等. 大黄煎剂保留灌肠治疗肝性脑病的多中心临床研究[J]. 辽宁中医杂志, 2011, 38( 7): 1364- 1366. DOI: 10.13192/j.ljtcm.2011.07.118.huanggy.032. [21] WANG N, WANG MG, MAO DW, et al. Clinical observation of rhubarb decoction in the treatment of type A hepatic encephalopathy[J]. Lishizhen Med Mater Med Res, 2015, 26( 5): 1169- 1171. DOI: 10.3969/j.issn.1008-0805.2015.05.053.王娜, 王明刚, 毛德文, 等. 大黄煎剂治疗A型肝性脑病的临床疗效观察[J]. 时珍国医国药, 2015, 26( 5): 1169- 1171. DOI: 10.3969/j.issn.1008-0805.2015.05.053. [22] QIU H, HUANG GY, MAO DW, et al. Orthoplan to screen the optimum scheme of retention Enema in treatment of hepatic encephalopathy with rhubarb decoction[J]. J Tradit Chin Med, 2010, 51( 11): 990- 992. DOI: 10.13288/j.11-2166/r.2010.11.011.邱华, 黄古叶, 毛德文, 等. 正交设计筛选大黄煎剂保留灌肠治疗肝性脑病最佳方案的研究[J]. 中医杂志, 2010, 51( 11): 990- 992. DOI: 10.13288/j.11-2166/r.2010.11.011. [23] TAN LC. Observation and nursing care of rhubarb decoction retention Enema in the treatment of hepatic encephalopathy[J]. Liaoning J Tradit Chin Med, 2007, 34( 8): 1116- 1117. DOI: 10.13192/j.ljtcm.2007.08.96.tanlch.051.谭柳纯. 大黄煎剂保留灌肠治疗肝性脑病疗效观察及护理[J]. 辽宁中医杂志, 2007, 34( 8): 1116- 1117. DOI: 10.13192/j.ljtcm.2007.08.96.tanlch.051. [24] WU FL, LIAO NS, WEI JR, et al. Research progress of technical specification of the treatment of hepatic encephalopathy by Dahuang Decoction retention Enema[J]. West J Tradit Chin Med, 2023, 36( 6): 141- 144. DOI: 10.12174/j.issn.2096-9600.2023.06.34.吴凤兰, 廖南盛, 卫家润, 等. 大黄煎剂保留灌肠治疗肝性脑病的技术规范研究进展[J]. 西部中医药, 2023, 36( 6): 141- 144. DOI: 10.12174/j.issn.2096-9600.2023.06.34. [25] ZHANG GF, CAI YY, LIN L, et al. Protective mechanism of rhubarb decoction against inflammatory damage of brain tissue in rats with mild hepatic encephalopathy: A study based on the PI3K/AKT/mTOR signaling pathway[J]. J Clin Hepatol, 2024, 40( 2): 312- 318. DOI: 10.12449/JCH240215.张广发, 蔡颖莹, 林龙, 等. 基于PI3K/AKT/mTOR信号通路探讨大黄煎剂对轻微型肝性脑病大鼠脑组织炎症损伤的保护机制[J]. 临床肝胆病杂志, 2024, 40( 2): 312- 318. DOI: 10.12449/JCH240215. [26] DU YQ, WANG M, XU J, et al. Investigation of therapeutic effects of rhubarb decoction retention Enema on minimal hepatic encephalopathy in rats based on 16S rDNA gene sequencing and bile acid metabolomics[J]. J Pharm Biomed Anal, 2023, 230: 115392. DOI: 10.1016/j.jpba.2023.115392. [27] DU YQ, WANG M, HUANG GC, et al. Therapeutic effect of retention Enema with compound rhubarb decoction on a rat model of minimal hepatic encephalopathy based on bile acid metabolomics[J]. J Clin Hepatol, 2023, 39( 10): 2348- 2357. DOI: 10.3969/j.issn.1001-5256.2023.10.012.杜沅沁, 王萌, 黄国初, 等. 基于胆汁酸代谢组学探讨复方大黄煎剂保留灌肠对轻微型肝性脑病大鼠模型的治疗作用[J]. 临床肝胆病杂志, 2023, 39( 10): 2348- 2357. DOI: 10.3969/j.issn.1001-5256.2023.10.012. [28] YAO C, HUANG GC, WANG M, et al. Chinese herbal medicine formula jieduhuayu granules improves cognitive and neurophysiological functions in patients with cirrhosis who have minimal hepatic encephalopathy: A randomized controlled trial[J]. Complement Ther Med, 2014, 22( 6): 977- 985. DOI: 10.1016/j.ctim.2014.10.005. [29] YAO C, WANG M, YAO F, et al. Clinical observation on intelligence test and neurophysiological changes of patients with mild hepatic encephalopathy treated with Jiedu Huayu recipe[J]. Lishizhen Med Mater Med Res, 2014, 25( 4): 890- 892. DOI: 10.3969/j.issn.1008-0805.2014.04.052.姚春, 王萌, 姚凡, 等. 解毒化瘀方对轻微型肝性脑病患者智力测验及神经电生理学改变的临床观察[J]. 时珍国医国药, 2014, 25( 4): 890- 892. DOI: 10.3969/j.issn.1008-0805.2014.04.052. [30] MAO DW, QIU H, HUANG GY, et al. Experimental study on mechanism of detoxification and removing blood stasis formula II in preventing and treating hepatic encephalopathy in rats with AHG[J]. Tianjin J Tradit Chin Med, 2006, 23( 6): 486- 489. DOI: 10.3969/j.issn.1672-1519.2006.06.016.毛德文, 邱华, 黄古叶, 等. 解毒化瘀Ⅱ方防治急性肝衰竭肝性脑病的实验机制研究[J]. 天津中医药, 2006, 23( 6): 486- 489. DOI: 10.3969/j.issn.1672-1519.2006.06.016. -